Unlike reports from other phase I studies of IGF-1R targeting antibodies, we did not observe any hyperglycemia, although we excluded patients with a history of diabetes mellitus or patients with baseline hemoglobin A1c of >6 %, a lower cut-off than other studies that used 8 % as the eligibility criterion. Here, IGF1R is linked to Hyperglycemia.